Why be a vaccine company? ; DIA18: Value-based contracts pose more questions than answers; FDA to pub surrogate endpoints used in cancer drug approvals; Jardiance shows potential in type 1 diabetes, clearing Phase 3 tests
GW Pharma got a green light for its plant-derived cannibidiol Epidiolex in two rare forms of epilepsy, but must wait on DEA rescheduling before launching the drug.
Lower margins and pricey manufacturing are hallmarks of vaccine making. Yet the drugs can provide a steady, and often competition-free, source of revenue.
Drugmakers and payers are still figuring out what data are needed to support a new wave of pricing agreements and how to collect that information earlier.
Mobile campaigns continue to dominate the advertising space, but with good reason. Geo-location technology is providing new and effective ways of reaching target audiences.
It's part of a broader effort to reassess how the agency evaluates treatment benefit amid rapid clinical advances. But the approach is not without critics.
Advance your Medical Affairs initiatives with patient-centric insights to drive better engagement and adoption. Real-world patient-level data delivers an unparalleled view of disease burden and networks of care. Download our whitepaper
Opinion Poll
BROUGHT TO YOU BY MEDIDATA
There's been a lot of buzz around patient centricity. Every day this week, we'll be asking a question to get to the heart of its impact on the industry.
How much does patient burden impact patient retention and recruitment?
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected] You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.
